Document is current
Any future updates will be listed below
-
Authors
Sanjuan-Ruiz, Inmaculada
Serneels, Lutgarde
Craessaerts, Katleen
Goate, Alison
Annaert, Wim
Chávez-Gutiérrez, Lucía
Shi, Yonggang
Sheikh-Bahaei, Nasim
Jen, Joanna C.
Ramos, Eliana Marisa
Campan, Mihaela
Ward, Pamela M.
Magaki, Shino
Bartlone, Kelly
Vinters, Harry V.
,
Craig, David W.
Ringman, John M.
De Strooper, Bart
-
Funding
Funding for this research was provided by:
KULeuven (Opening the future)
alzheimer's Association USA
Fonds Wetenschappelijk Onderzoek
SAO-FRA
European union (ERC-834682 CELLPHASE_AD)
UK Dementia Research Institute
UKRI-MRC (MR/Y014847/1)
Queen Elisabeth Medical Foundation
- License Information
-
More Information
Article History
Received: 26 July 2025
Accepted: 19 August 2025
First Online: 20 October 2025
Declarations
:
: All animal experiments were approved by the Ethical Committee for Animal Experimentation at the University of Leuven.
: Informed consent was obtained from the index patient in this study.
: B.D.S. is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. B.D.S. is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. AMG is a member of the SRB for Genentech and Muna Therapeutics. She has consulted for Merck. J.M.R. receives research support from Avid Pharmaceuticals and has been a consultant for Eisai Pharmaceuticals.
